Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer
Jun Watanabe(Kansai Medical University), Takayuki Yoshino(University of Tsukuba), Hitoshi Ojima(Gunma Prefectural Cardiovascular Center), Hisatsugu Ohori(Tohoku University Hospital), Kohei Shitara(National Cancer Center Hospital East), Katsuya Tsuchihara(Chiba Cancer Center), Keisuke Miwa(Kurume University), Takeo Sato(Kitasato University), Atsuo Takashima(National Cancer Center Hospital East), Hiroyuki Uetake(National Hospital Organization), Naoya Akazawa(Sendai Medical Center), Toshihiro Misumi(Yokohama City University), Kiwamu Akagi(Kuwait University), Kentaro Yamazaki(Shizuoka Cancer Center), Yasuhiro Yuasa(Tokushima Red Cross Hospital), Yoshito Komatsu(Hokkaido University Hospital), Manabu Shiozawa(Kanagawa Prefectural Hospital Organization), Takeshi Naitoh(Kitasato University), Eiji Oki(Kyushu University), Akitaka Makiyama(Japan Community Healthcare Organization), Mitsuru Yokota(Kurashiki Central Hospital), Kei Muro(Aichi Cancer Center), Takeshi Kato(Osaka National Hospital), Kouji Yamamoto(Yokohama City University), Hirofumi Yasui(Shizuoka Cancer Center), Junpei Soeda(Takeda (Japan)), Atsushi Ochiai(Tokyo University of Science), Masamitsu Hihara(Takeda (Japan))
Cited by 255
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k